Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Study Details
Study Description
Brief Summary
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma.
PURPOSE: This phase II trial is studying the side effects of giving lenalidomide together with rituximab and to see how well it works in treating patients with recurrent or refractory multiple myeloma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
Primary
- To determine the safety and efficacy, as determined by response rate (complete response [CR] + near CR + partial response), of lenalidomide administered with rituximab in patients with relapsed and/or refractory CD20+ multiple myeloma.
Secondary
-
To assess the effects of this regimen on patient lymphocyte subsets (T, B, and NK cells) in peripheral blood and bone marrow samples from these patients.
-
To perform detailed phenotypic analyses of NK cells in patient blood and bone marrow samples at baseline and post-treatment.
OUTLINE: Patients receive oral lenalidomide once daily on days 1-21. Treatment with lenalidomide repeats every 28 days for at least 4 courses. Patients also receive rituximab IV once weekly in weeks 2-5 and in week 13. Patients with stable disease then receive rituximab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Peripheral blood samples are collected at baseline, and after courses 2 and 4. Samples are examined by flow cytometry for lymphocyte subset analysis (T-, B-, and NK-cell percentages and absolute numbers) and NK-cell phenotyping (CD16, CD56, NKG2D expression). Samples are also examined by immunologic assays of isolated peripheral blood mononuclear cells. Bone marrow aspirate samples are also collected at baseline and after course 2. Bone marrow mononuclear cells are isolated and evaluated by CD138+ plasma cell selection, ex vivo antibody-dependent cellular cytotoxicity assays, and bone marrow lymphocyte subset analysis.
After completion of study therapy, patients are followed at 30 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Lenalidomide and Rituximab This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks. |
Biological: rituximab
Drug: lenalidomide
Genetic: microarray analysis
Other: flow cytometry
Other: laboratory biomarker analysis
|
Outcome Measures
Primary Outcome Measures
- Final Response Rate After 4 Courses of Treatment [2 years]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed CD20+ multiple myeloma
-
CD20+ disease defined as co-expression of CD20 on ≥ 25% of the clonal plasma cell population as defined by immunohistochemical or flow cytometric staining of a bone marrow or plasmacytoma specimen obtained at study entry
-
For flow cytometry, this is determined by calculating the frequency of CD20+ CD138+ double-positive cells within the total CD138+ plasma cell population
-
For immunohistochemistry, this is determined by dual staining for CD20 and the involved clonal light chain (kappa or lambda), with a determination of the percent double-positive (≤ 25% or ≥ 25%)
-
Symptomatic multiple myeloma that has relapsed or progressed after at least 1 prior anti-myeloma therapeutic regimen
PATIENT CHARACTERISTICS:
-
ECOG performance status 0-2
-
Life expectancy > 16 weeks (4 months)
-
ANC ≥ 1,500/μL (unless low ANC due to multiple myeloma)
-
Platelets ≥ 100,000/μL (unless low platelets are due to multiple myeloma)
-
Serum bilirubin ≤ 2.0 mg/dL
-
AST, ALT, and alkaline phosphatase < 3 times upper limit of normal
-
Serum creatinine ≤ 2.5 mg/dL
-
Able to understand the investigational nature of lenalidomide and rituximab combination therapy and to give informed consent
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective double-method contraception at least 28 days before, during, and for at least 28 days after completion or discontinuation of study treatment
-
Able to take acetylsalicylic acid (ASA) (325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin)
-
Prior malignancies with a disease free interval of ≥ 5 years allowed
-
No history of thromboembolic disease within the past 6 months, regardless of anticoagulation
-
No myocardial infarction within the past 6 months
-
No New York Hospital Association class III or IV heart failure
-
No uncontrolled angina
-
No severe uncontrolled ventricular arrhythmias
-
No active hepatitis B or C infection
-
No HIV 1or 2 positivity
-
No acute ischemia or active conduction system abnormalities as evidenced by ECG
-
No history of hypersensitivity reactions to lenalidomide, thalidomide, or rituximab
-
No other medical condition or laboratory evaluation that, in the treating physician's or principal investigators' opinion, makes the patient unsuitable to participate in this clinical trial
-
No concurrent active malignancy other than nonmelanoma skin cancers or carcinoma-in-situ of the cervix
PRIOR CONCURRENT THERAPY:
-
At least 3 weeks since prior therapy, including radiotherapy
-
Prior lenalidomide or thalidomide allowed
-
No prior rituximab
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10021 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Hani Hassoun, MD, Memorial Sloan Kettering Cancer Center
- Principal Investigator: Heather Landau, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Mskcc 07-070
- P30CA008748
- MSKCC-07070
- NCT00590486
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Lenalidomide and Rituximab |
|---|---|
| Arm/Group Description | This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks. |
| Period Title: Overall Study | |
| STARTED | 3 |
| COMPLETED | 3 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Lenalidomide and Rituximab |
|---|---|
| Arm/Group Description | This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks. |
| Overall Participants | 3 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
1
33.3%
|
| >=65 years |
2
66.7%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
1
33.3%
|
| Male |
2
66.7%
|
Outcome Measures
| Title | Final Response Rate After 4 Courses of Treatment |
|---|---|
| Description | |
| Time Frame | 2 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Lenalidomide and Rituximab |
|---|---|
| Arm/Group Description | This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks. |
| Measure Participants | 3 |
| Stable Disease (SD) |
2
66.7%
|
| Progression of Disease (POD) |
1
33.3%
|
Adverse Events
| Time Frame | ||
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Lenalidomide and Rituximab | |
| Arm/Group Description | This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks. | |
All Cause Mortality |
||
| Lenalidomide and Rituximab | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| Lenalidomide and Rituximab | ||
| Affected / at Risk (%) | # Events | |
| Total | 1/3 (33.3%) | |
| Respiratory, thoracic and mediastinal disorders | ||
| Pulmonary/upper respiratory | 1/3 (33.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Lenalidomide and Rituximab | ||
| Affected / at Risk (%) | # Events | |
| Total | 3/3 (100%) | |
| Blood and lymphatic system disorders | ||
| Hemoglobin | 1/3 (33.3%) | 1 |
| PT INR | 1/3 (33.3%) | 1 |
| Leukocytes (total WBC) | 2/3 (66.7%) | 2 |
| Lymphopenia | 1/3 (33.3%) | 1 |
| Neutrophils/granulocytes | 3/3 (100%) | 3 |
| Gastrointestinal disorders | ||
| Constipation | 1/3 (33.3%) | 1 |
| Nervous system disorders | ||
| Neuropathy: sensory | 2/3 (66.7%) | 2 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Hani Hassoun |
|---|---|
| Organization | Memorial Sloan Kettering Cancer Center |
| Phone | 212-639-3228 |
| hassounh@mskcc.org |
- Mskcc 07-070
- P30CA008748
- MSKCC-07070
- NCT00590486